ArticleAmerican journal of cancer research2015
OPCML is frequently methylated in human colorectal cancer and its restored expression reverses EMT via downregulation of smad signaling.
Article in American journal of cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 35 citations in OpenAlex.
- A Genome-Wide Association Study of Colorectal Cancer Mortality Outcomes Among Individuals of African and Admixture Ancestry.Molecular carcinogenesis · 2026Article
- Genetic Factors Related to the Development or Progression of Mesoamerican Endemic Nephropathy.International journal of molecular sciences · 2025Review
- Article
- Transcriptomic Profiling of Tetrodotoxin-Induced Neurotoxicity in Human Cerebral Organoids.Marine drugs · 2023Article
- Neuroglobin plays as tumor suppressor by disrupting the stability of GPR35 in colorectal cancer.Clinical epigenetics · 2023Article
- Article
- Expression and promoter methylation status of OPCML and its functions in the inhibition of cell proliferation, migration, and invasion in breast cancer.Breast cancer (Tokyo, Japan) · 2021Article
- Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers.Cancer gene therapy · 2021Review
- Aberrant methylation of the 16q23.1 tumor suppressor gene ADAMTS18 promotes tumorigenesis and progression of clear cell renal cell carcinoma.Genes & genomics · 2021Article
- Crosstalk Between DNA Methylation and Gene Mutations in Colorectal Cancer.Frontiers in oncology · 2021Article
- Multiple omics analysis of the protective effects of SFN on estrogen-dependent breast cancer cells.Molecular biology reports · 2020Article
- [Luteolin reverses OPCML methylation to inhibit proliferation of breast cancer MDA-MB-231 cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- Analysis of Copy-Number Variations and Feline Mammary Carcinoma Survival.Scientific reports · 2020Article
- The phosphoinositide hydrolase phospholipase C delta1 inhibits epithelial-mesenchymal transition and is silenced in colorectal cancer.Journal of cellular physiology · 2019Article
- Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions.Nature communications · 2019Article
- Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis.The Journal of investigative dermatology · 2019Article
- Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases.Clinical epigenetics · 2019Article
- Article
- Effect of luteolin on the methylation status of the OPCML gene and cell growth in breast cancer cells.Experimental and therapeutic medicine · 2018Article
- Loss of opioid binding protein/cell adhesion molecule-like gene expression in gastric cancer.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence has indicated that the expression of OPCML gene is frequently altered in a variety of cancers. We previously demonstrated that the OPCML gene is a target of epigenetic inactivation and its gene product exhibits tumor-suppressive properties. However, little is known regarding the effects and mechanisms of OPCML in colon cancer. We show that the loss or downregulation of OPCML is associated with its promoter hypermethylation. Methylation of the OPCML promoter was detected in all tumors and tumor-adjacent tissues, but lower methylation in normal colon tissues. The drug-induced release of epigenetic silencing was able to restore OPCML expression and the re-expression led to the suppression of cell growth. Furthermore, the increase in OPCML expression reversed a partial epithelial-to-mesenchymal (EMT)-like transition. Cell migration and invasiveness were also inhibited in response to OPCML upregulation. These actions were mediated through the inactivation of TGFβ-Smad signaling pathways. In addition, OPCML expression was associated with two upstream nuclear receptors (ERRa and RORa). Altogether, our study reveals OPCML as a potential tumor suppressor gene epigenetically silenced in colon cancer. Our study will help to elucidate the anti-invasive mechanisms of OPCML and establish new chemotherapeutic strategies for human colon cancer.
Indexed as
Identifiers
26175934PMC4497432W2432996367What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.